prIME Oncology invites you to view a daily Webcast of interviews with Nordic Region Experts from the 45th ASCO Annual Meeting in Orlando, Florida.

Follow the links below to view the expert interviews conducted by Lee Lokey, MD discussing key abstracts presented on Saturday, May 30 and Sunday, May 31, 2009.

View Expert Interview with Jan-Erik Frödin, MD, and Jan-Olof Fernberg, MD

View Expert Interview with Stein Sundstrøm, MD

This clinical update focuses on the following data releases:

• Abstract #4000: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study

• Abstract #LBA4: A phase III trial comparing mFolfox6 to mFolfox6 + bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

• Abstract #10550: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors

• Abstract #8001: SATURN: A double-blind randomized phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC

• Abstract #LBA8002: A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

• Abstract #CRA8000: Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced NSCLC